Genor Biopharma Holdings Limited 6998.HK Stock
Genor Biopharma Holdings Limited Price Chart
Genor Biopharma Holdings Limited 6998.HK Financial and Trading Overview
Genor Biopharma Holdings Limited stock price | 1.33 HKD |
Previous Close | 1.66 HKD |
Open | 1.66 HKD |
Bid | 1.63 HKD x N/A |
Ask | 1.68 HKD x N/A |
Day's Range | 1.6 - 1.71 HKD |
52 Week Range | 1.57 - 5.95 HKD |
Volume | 362.5K HKD |
Avg. Volume | 104.54K HKD |
Market Cap | 840.1M HKD |
Beta (5Y Monthly) | 0.57862 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.43 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.81 HKD |
6998.HK Valuation Measures
Enterprise Value | -699077696 HKD |
Trailing P/E | N/A |
Forward P/E | -1.7849462 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 52.730106 |
Price/Book (mrq) | 0.4618809 |
Enterprise Value/Revenue | -43.879 |
Enterprise Value/EBITDA | 0.934 |
Trading Information
Genor Biopharma Holdings Limited Stock Price History
Beta (5Y Monthly) | 0.57862 |
52-Week Change | -56.65% |
S&P500 52-Week Change | 20.43% |
52 Week High | 5.95 HKD |
52 Week Low | 1.57 HKD |
50-Day Moving Average | 1.95 HKD |
200-Day Moving Average | 2.32 HKD |
6998.HK Share Statistics
Avg. Volume (3 month) | 104.54K HKD |
Avg. Daily Volume (10-Days) | 113.9K HKD |
Shares Outstanding | 506.08M |
Float | 303.92M |
Short Ratio | N/A |
% Held by Insiders | 8.77% |
% Held by Institutions | 31.23% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -4928.54% |
Gross Margin | 93.82% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -19.71% |
Return on Equity (ttm) | -33.98% |
Income Statement
Revenue (ttm) | 15.93M HKD |
Revenue Per Share (ttm) | 0.03 HKD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -748555008 HKD |
Net Income Avi to Common (ttm) | -730214016 HKD |
Diluted EPS (ttm) | -1.58 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 1.59B HKD |
Total Cash Per Share (mrq) | 3.17 HKD |
Total Debt (mrq) | 28.59M HKD |
Total Debt/Equity (mrq) | 1.58 HKD |
Current Ratio (mrq) | 6.606 |
Book Value Per Share (mrq) | 3.594 |
Cash Flow Statement
Operating Cash Flow (ttm) | -577606976 HKD |
Levered Free Cash Flow (ttm) | -371351008 HKD |
Profile of Genor Biopharma Holdings Limited
Country | Hong Kong |
State | N/A |
City | Shanghai |
Address | Building 3 |
ZIP | 201203 |
Phone | 86 21 6169 0700 |
Website | https://www.genorbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 264 |
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB267, and GB266 for the treatment of cancer. The company was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.
Q&A For Genor Biopharma Holdings Limited Stock
What is a current 6998.HK stock price?
Genor Biopharma Holdings Limited 6998.HK stock price today per share is 1.33 HKD.
How to purchase Genor Biopharma Holdings Limited stock?
You can buy 6998.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genor Biopharma Holdings Limited?
The stock symbol or ticker of Genor Biopharma Holdings Limited is 6998.HK.
Which industry does the Genor Biopharma Holdings Limited company belong to?
The Genor Biopharma Holdings Limited industry is Biotechnology.
How many shares does Genor Biopharma Holdings Limited have in circulation?
The max supply of Genor Biopharma Holdings Limited shares is 512.53M.
What is Genor Biopharma Holdings Limited Price to Earnings Ratio (PE Ratio)?
Genor Biopharma Holdings Limited PE Ratio is now.
What was Genor Biopharma Holdings Limited earnings per share over the trailing 12 months (TTM)?
Genor Biopharma Holdings Limited EPS is -1.43 HKD over the trailing 12 months.
Which sector does the Genor Biopharma Holdings Limited company belong to?
The Genor Biopharma Holdings Limited sector is Healthcare.
Genor Biopharma Holdings Limited 6998.HK included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
Nasdaq EM Plus Korea Small Cap NQEMKRSCGBP | 1476.35 GBP 1888.16 USD |
<0.01
|
— — | 1476.35 GBP 1888.16 USD | 1476.35 GBP 1888.16 USD | — - | — — |
- {{ link.label }} {{link}}